Table 4. Univariate and multivariate Cox proportional hazards regression model of clinical and imaging variables predicting biochemical recurrence: patients with negative surgical margins.
| Covariate | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Age, years | 0.99 (0.94–1.05) | 0.7 | - | - |
| BMI | 1.03 (0.93–1.12) | 0.5 | - | - |
| Preoperative PSA, ng/ml | 1.07 (1.04–1.09) | <0.0001 | 1.05 (1.02–1.08) | 0.003 |
| Race | ||||
| White | 1 | - | - | - |
| Black | 0.62 (0.14–1.83) | 0.4 | - | - |
| Other | 0.98 (0.16–3.43) | 1 | - | - |
| Clinical stage | 3.54 (1.35–8.42) | 0.01 | 1.89 (0.69–4.75) | 0.2 |
| Biopsy Gleason score | 6.71 (3.26–15.28) | <0.0001 | 4.89 (2.24–11.61) | <0.0001 |
| MRI prostate volume, cc | 0.99 (0.96–1.01) | 0.3 | - | - |
| MRI lesions, no | 0.79 (0.52–1.17) | 0.3 | - | - |
| MP—MRI suspicion score | 3.81 (1.83–8.70) | 0.0002 | 1.84 (0.84–4.41) | 0.1 |
| mECE | 5.45 (2.30–14.29) | 0.0001 | 3.37 (1.35–9.32) | 0.009 |
| mSVI | 1.60 (0.09–7.65) | 0.7 | - | - |
BMI = body mass index; CI = confidence interval; HR = hazard ratio; PSA = prostate-specific antigen; MP-MRI = multiparametric magnetic resonance imaging; MRI = magnetic resonance imaging. Statistical significance denoted by bold face.